Quote:Of course, perhaps she is not one of the three or so (of the 5/7) that was NED. (And still has remnants or whatever they look at).
I had figured the patients just received leronlimab for whatever length of time the trial lasted or at best until the safety hold came down. Which may explain the one patient who relapsed and the one who's tumor is stable. Coming from Canada, Mrs. Peterson would not be subject to the FDA's hold. Hopefully the relapsed patient and the one with the stable tumor have requested to use it again under EIND.